Developer docs
API playgroundTry for free, no card

Search company profiles

Aexon Labs

Full company profile

uuid00rrjju

Namestring
Aexon Labs
Legal namestring
Aexon Labs. Inc
Websiteurl
aexonlabs.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Aexon Labs, Inc. is a pre-revenue, privately held pharmaceutical R&D company domiciled in Delaware (headquartered at 16192 Coastal Hwy, Lewes) that is developing a portfolio of dual non-sulfonamide orexin receptor agonists for neurodegenerative and neurological disorders. The company's core technology is a first-in-class non-sulfonamide platform targeting both OX1R and OX2R receptors with an integrated cathepsin H (CTSH) inhibition mechanism, designed to address neuroinflammation underlying narcolepsy, synucleinopathies (Parkinson's disease, Dementia with Lewy Body, Multiple System Atrophy), and Alzheimer's disease. The platform comprises named lead compounds AEX-23, AEX-19, and AEX-24, each characterized by OX1R agonist activity, neurite outgrowth effects, and Cathepsin D modulation, with AEX-24 specifically positioned for alpha-synuclein degradation enhancement. Compounds are designed as Lipinski-rule-of-five-compliant aromatic heterocycles with solubility characterized across pH 0 to pH 13. The company has no current commercial revenue, no disclosed funding rounds, and no headcount data; its stated go-to-market pathway is licensing agreements or partnerships with established pharmaceutical companies for global commercialization contingent on successful clinical development. Co-founders Eric Konofal (MD, PhD; 88+ patents, 76+ peer-reviewed publications, also co-founder of NASDAQ-listed NLS Pharmaceutics) and Anh-Tuan Lormier (PhD Chemistry; co-founder/President of CayLab) lead the scientific program, and the company has presented at the ASCP Annual Meetings in 2024 and 2025.

Short descriptiontext

Aexon Labs is a pre-revenue Delaware-based biotech developing non-sulfonamide dual orexin receptor agonists (AEX-23, AEX-19, AEX-24) targeting neuroinflammation for narcolepsy, Parkinson's, and Alzheimer's disease, with planned commercialization via pharmaceutical licensing or partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLewes, United States
HQ citystring
Lewes
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orexin receptor agonists, neurodegenerative disease therapeutics, CNS drug discovery, narcolepsy therapeutics, medicinal chemistry research
Industry1 code
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical R&D
Social media profiles3 records
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aexon Labs is a biotechnology R&D company developing a portfolio of novel non-sulfonamide dual orexin receptor agonist compounds (AEX-23, AEX-19, AEX-24) that target both OX1R and OX2R receptors with integrated Cathepsin H (CTSH) inhibitory properties for neurodegenerative and CNS disorders including narcolepsy type 1, Parkinson's disease, and Alzheimer's disease. The compounds are designed as innovative aromatic heterocyclic molecules following Lipinski's rule of five, protected by international PCT patent application WO2024115797 (filed 30/12/2022). The company is pre-revenue and intends to commercialize approved therapeutics through licensing or partnership with established pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aexon Labs is a pharmaceutical/biotechnology company developing a portfolio of innovative therapeutic compounds for neurodegenerative disorders. The core offering is the AEX Compounds platform—a first non-sulfonamide dual orexin receptor agonist technology targeting both OX1R and OX2R receptors, with specific named compounds including AEX-23, AEX-19, and AEX-24. These compounds also incorporate Cathepsin H (CTSH) inhibitory properties and are being developed for conditions including narcolepsy with cataplexy, synucleinopathies (Parkinson's disease), and Alzheimer's disease. The company has an international PCT patent portfolio (WO2024115797) protecting their novel aromatic heterocyclic compounds designed with favorable physicochemical properties following Lipinski's rule of five.

Product and service4 records
1AEX Compounds Platform (Dual Non-Sulfonamide Orexin Receptor Agonists)
CategoryBiopharmaceutical R&D Platform
Description

A proprietary drug-discovery platform of innovative aromatic heterocyclic dual orexin receptor agonists targeting OX1R and OX2R with integrated Cathepsin H (CTSH) inhibitory properties, designed with favorable Lipinski-rule-of-five physicochemical and biopharmaceutical properties. Intended for development into therapeutics for neurodegenerative disorders including narcolepsy, Parkinson's disease, and Alzheimer's disease, with eventual commercialization via licensing or partnership with large pharmaceutical companies.

2AEX-23 Compound
CategoryNeuroscience Drug Candidate
Description

A specific AEX lead compound demonstrating significant OX1R agonist activity combined with positive effects on neurite outgrowth, suggesting modulation of neuronal health through pathways influencing alpha-synuclein dynamics and positioning it as a potential therapeutic candidate for Parkinson's disease.

3AEX-19 Compound
CategoryNeuroscience Drug Candidate
Description

A specific AEX lead compound showing effects at low concentrations on neurite growth, coupled with significant OX1R agonist activity and a moderate increase in Cathepsin D (CTSD) activity, suggesting potential neuroprotective benefits in Parkinson's disease.

4AEX-24 Compound
CategoryNeuroscience Drug Candidate
Description

A specific AEX lead compound demonstrating significant increase in Cathepsin D (CTSD) activity and OX1R agonist activity, suggesting potential to enhance alpha-synuclein degradation with promising therapeutic impact on Parkinson's disease.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Anavex develops sigma-1 receptor agonists for Alzheimer's, Rett syndrome, and Parkinson's — directly mirroring Aexon's CNS mechanism approach (sigma-1 + neuroinflammation) and providing a comparable small-cap neurodegenerative biotech peer.

TypeDirect peer
Description

Jazz markets Xywav (oxybate) and Sunosi (solriamfetol) for narcolepsy with cataplexy and excessive daytime sleepiness, directly competing for the same NT1 patient population that Aexon's dual orexin agonist platform targets.

TypeEmerging player
Description

Axsome is a CNS-focused commercial-stage biotech with approved therapies (e.g., Auvelity, Sunosi-related assets) addressing high-unmet-need neurological indications, providing a comparable commercial-stage CNS biotech template for Aexon's future trajectory.

TypeEmerging player
Description

Sage develops CNS therapies for depression and neurology, including Zurzuvae. It shares Aexon's profile of targeting high-unmet-need CNS indications with novel mechanisms and is a relevant comp for biotech-stage CNS valuations and partnership dynamics.

5Cassava Sciences
TypeEmerging player
Description

Cassava (simufilam) is a clinical-stage biotech focused on Alzheimer's disease. As a single-asset CNS neurodegenerative company, it offers a comparable public-market template for Aexon's AD program trajectory.

TypeDirect peer
Description

Denali is a clinical-stage biotech developing therapies for neurodegeneration (PD, AD, ALS) with novel small molecules targeting lysosomal function and neuroinflammation — directly aligned with Aexon's cathepsin/neuroinflammation thesis.

TypeBroad incumbent
Description

Takeda developed TAK-994, the leading dual orexin receptor agonist for narcolepsy that was discontinued due to hepatotoxicity. As the originator of the orexin therapeutic class, Takeda is the most direct reference point for Aexon's non-sulfonamide re-entry strategy.

TypeDirect peer
Description

NLS Pharmaceutics (NASDAQ: NLSP) is co-founded by Aexon's co-founder Eric Konofal and focuses on rare CNS disorders, including orexin-related therapies. It is the closest direct peer in terms of scientific lineage, therapeutic focus, and capital-market profile.

TypeBroad incumbent
Description

Biogen is a major player in Alzheimer's (Aduhelm, Leqembi via partnership) and Parkinson's, with established CNS development infrastructure that could serve as both a competitor and a potential acquirer/partner for Aexon's neurodegenerative pipeline.

TypeDirect peer
Description

Avadel's Lumryz is an extended-release oxybate approved for narcolepsy with cataplexy. It competes head-to-head with Jazz's Xywav in the same EDS/cataplexy market Aexon is targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aexon Labs

Biopharmaceutical R&Daexonlabs.com

Aexon Labs is a pre-revenue Delaware-based biotech developing non-sulfonamide dual orexin receptor agonists (AEX-23, AEX-19, AEX-24) targeting neuroinflammation for narcolepsy, Parkinson's, and Alzheimer's disease, with planned commercialization via pharmaceutical licensing or partnerships.

What Aexon Labs does

Aexon Labs, Inc. is a pre-revenue, privately held pharmaceutical R&D company domiciled in Delaware (headquartered at 16192 Coastal Hwy, Lewes) that is developing a portfolio of dual non-sulfonamide orexin receptor agonists for neurodegenerative and neurological disorders. The company's core technology is a first-in-class non-sulfonamide platform targeting both OX1R and OX2R receptors with an integrated cathepsin H (CTSH) inhibition mechanism, designed to address neuroinflammation underlying narcolepsy, synucleinopathies (Parkinson's disease, Dementia with Lewy Body, Multiple System Atrophy), and Alzheimer's disease. The platform comprises named lead compounds AEX-23, AEX-19, and AEX-24, each characterized by OX1R agonist activity, neurite outgrowth effects, and Cathepsin D modulation, with AEX-24 specifically positioned for alpha-synuclein degradation enhancement. Compounds are designed as Lipinski-rule-of-five-compliant aromatic heterocycles with solubility characterized across pH 0 to pH 13. The company has no current commercial revenue, no disclosed funding rounds, and no headcount data; its stated go-to-market pathway is licensing agreements or partnerships with established pharmaceutical companies for global commercialization contingent on successful clinical development. Co-founders Eric Konofal (MD, PhD; 88+ patents, 76+ peer-reviewed publications, also co-founder of NASDAQ-listed NLS Pharmaceutics) and Anh-Tuan Lormier (PhD Chemistry; co-founder/President of CayLab) lead the scientific program, and the company has presented at the ASCP Annual Meetings in 2024 and 2025.

Aexon Labs firmographics

Firmographics
Name
Aexon Labs
Legal name
Aexon Labs. Inc
Website
https://aexonlabs.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Aexon Labs is a pre-revenue Delaware-based biotech developing non-sulfonamide dual orexin receptor agonists (AEX-23, AEX-19, AEX-24) targeting neuroinflammation for narcolepsy, Parkinson's, and Alzheimer's disease, with planned commercialization via pharmaceutical licensing or partnerships.
Ownership category
akta.pro rank

Aexon Labs industry classification

Industry
Product category
Biopharmaceutical R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Orexin receptor agonists
  • Neurodegenerative disease therapeutics
  • CNS drug discovery
  • Narcolepsy therapeutics
  • Medicinal chemistry research

Where Aexon Labs is headquartered

Location

Headquarters

HQ city
Lewes
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aexon Labs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Distribution channels1 record

Marketing channels3 records

Aexon Labs product offering

Product offering

Core offering

Aexon Labs is a biotechnology R&D company developing a portfolio of novel non-sulfonamide dual orexin receptor agonist compounds (AEX-23, AEX-19, AEX-24) that target both OX1R and OX2R receptors with integrated Cathepsin H (CTSH) inhibitory properties for neurodegenerative and CNS disorders including narcolepsy type 1, Parkinson's disease, and Alzheimer's disease. The compounds are designed as innovative aromatic heterocyclic molecules following Lipinski's rule of five, protected by international PCT patent application WO2024115797 (filed 30/12/2022). The company is pre-revenue and intends to commercialize approved therapeutics through licensing or partnership with established pharmaceutical companies.

Product overview

Aexon Labs is a pharmaceutical/biotechnology company developing a portfolio of innovative therapeutic compounds for neurodegenerative disorders. The core offering is the AEX Compounds platform—a first non-sulfonamide dual orexin receptor agonist technology targeting both OX1R and OX2R receptors, with specific named compounds including AEX-23, AEX-19, and AEX-24. These compounds also incorporate Cathepsin H (CTSH) inhibitory properties and are being developed for conditions including narcolepsy with cataplexy, synucleinopathies (Parkinson's disease), and Alzheimer's disease. The company has an international PCT patent portfolio (WO2024115797) protecting their novel aromatic heterocyclic compounds designed with favorable physicochemical properties following Lipinski's rule of five.

Differentiator

Problem solved

Functional benefit

Products and services

  • AEX Compounds Platform (Dual Non-Sulfonamide Orexin Receptor Agonists) A proprietary drug-discovery platform of innovative aromatic heterocyclic dual orexin receptor agonists targeting OX1R and OX2R with integrated Cathepsin H (CTSH) inhibitory properties, designed with favorable Lipinski-rule-of-five physicochemical and biopharmaceutical properties. Intended for development into therapeutics for neurodegenerative disorders including narcolepsy, Parkinson's disease, and Alzheimer's disease, with eventual commercialization via licensing or partnership with large pharmaceutical companies.
  • AEX-23 Compound A specific AEX lead compound demonstrating significant OX1R agonist activity combined with positive effects on neurite outgrowth, suggesting modulation of neuronal health through pathways influencing alpha-synuclein dynamics and positioning it as a potential therapeutic candidate for Parkinson's disease.
  • AEX-19 Compound A specific AEX lead compound showing effects at low concentrations on neurite growth, coupled with significant OX1R agonist activity and a moderate increase in Cathepsin D (CTSD) activity, suggesting potential neuroprotective benefits in Parkinson's disease.
  • AEX-24 Compound A specific AEX lead compound demonstrating significant increase in Cathepsin D (CTSD) activity and OX1R agonist activity, suggesting potential to enhance alpha-synuclein degradation with promising therapeutic impact on Parkinson's disease.

Companies that use Aexon Labs

Customer profile

Segments3 records

Ideal customer profiles1 record

Aexon Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aexon Labs partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Aexon Labs competitors and assessment

Company assessment

Emerging players

  • Anavex Life Sciences: Anavex develops sigma-1 receptor agonists for Alzheimer's, Rett syndrome, and Parkinson's — directly mirroring Aexon's CNS mechanism approach (sigma-1 + neuroinflammation) and providing a comparable small-cap neurodegenerative biotech peer.
  • Axsome Therapeutics: Axsome is a CNS-focused commercial-stage biotech with approved therapies (e.g., Auvelity, Sunosi-related assets) addressing high-unmet-need neurological indications, providing a comparable commercial-stage CNS biotech template for Aexon's future trajectory.
  • Sage Therapeutics: Sage develops CNS therapies for depression and neurology, including Zurzuvae. It shares Aexon's profile of targeting high-unmet-need CNS indications with novel mechanisms and is a relevant comp for biotech-stage CNS valuations and partnership dynamics.
  • Cassava Sciences: Cassava (simufilam) is a clinical-stage biotech focused on Alzheimer's disease. As a single-asset CNS neurodegenerative company, it offers a comparable public-market template for Aexon's AD program trajectory.

Direct peers

  • Jazz Pharmaceuticals: Jazz markets Xywav (oxybate) and Sunosi (solriamfetol) for narcolepsy with cataplexy and excessive daytime sleepiness, directly competing for the same NT1 patient population that Aexon's dual orexin agonist platform targets.
  • Denali Therapeutics: Denali is a clinical-stage biotech developing therapies for neurodegeneration (PD, AD, ALS) with novel small molecules targeting lysosomal function and neuroinflammation — directly aligned with Aexon's cathepsin/neuroinflammation thesis.
  • NLS Pharmaceutics: NLS Pharmaceutics (NASDAQ: NLSP) is co-founded by Aexon's co-founder Eric Konofal and focuses on rare CNS disorders, including orexin-related therapies. It is the closest direct peer in terms of scientific lineage, therapeutic focus, and capital-market profile.
  • Avadel Pharmaceuticals: Avadel's Lumryz is an extended-release oxybate approved for narcolepsy with cataplexy. It competes head-to-head with Jazz's Xywav in the same EDS/cataplexy market Aexon is targeting.

Broad incumbents

  • Takeda Pharmaceutical: Takeda developed TAK-994, the leading dual orexin receptor agonist for narcolepsy that was discontinued due to hepatotoxicity. As the originator of the orexin therapeutic class, Takeda is the most direct reference point for Aexon's non-sulfonamide re-entry strategy.
  • Biogen: Biogen is a major player in Alzheimer's (Aduhelm, Leqembi via partnership) and Parkinson's, with established CNS development infrastructure that could serve as both a competitor and a potential acquirer/partner for Aexon's neurodegenerative pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Aexon Labs social profiles

Digital presence

Aexon Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aexon Labs leadership team

Management profile

Number of profiles

Profiles2 records

Aexon Labs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aexon Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aexon Labs

What does Aexon Labs do?

Aexon Labs is a biotechnology R&D company developing a portfolio of novel non-sulfonamide dual orexin receptor agonist compounds (AEX-23, AEX-19, AEX-24) that target both OX1R and OX2R receptors with integrated Cathepsin H (CTSH) inhibitory properties for neurodegenerative and CNS disorders including narcolepsy type 1, Parkinson's disease, and Alzheimer's disease. The compounds are designed as innovative aromatic heterocyclic molecules following Lipinski's rule of five, protected by international PCT patent application WO2024115797 (filed 30/12/2022). The company is pre-revenue and intends to commercialize approved therapeutics through licensing or partnership with established pharmaceutical companies.

When was Aexon Labs founded?

Aexon Labs was founded in 2022. It employs 1 to 10 people.

Where is Aexon Labs based?

Aexon Labs is headquartered in Lewes, United States, in the North America region.

Who are Aexon Labs's main competitors?

Emerging players on record are Anavex Life Sciences, Axsome Therapeutics, Sage Therapeutics and Cassava Sciences. Direct peers are Jazz Pharmaceuticals, Denali Therapeutics, NLS Pharmaceutics and Avadel Pharmaceuticals. Broad incumbents are Takeda Pharmaceutical and Biogen.

Does Aexon Labs have an API?

No public API is recorded for Aexon Labs.

What industry is Aexon Labs in?

Aexon Labs's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon LabsNLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection for CNS disorders including narcolepsy, ADHD, and neurodegenerative diseases. The lead compound AEX-635 modulates MRP1 for enhanced neuroprotective effects. Preclinical data showed up to 80% reduction in cataplexy and over 70% increase in wakefulness in orexin knockout narcolepsy models. The companies are preparing IND-enabling studies and preclinical partnering discussions for Q4 2025.PR NewswireNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon LabsNLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecule therapeutics targeting arousal stability, cognition, and neuroprotection for CNS disorders. One lead compound, AEX-635, additionally modulates MRP1 to potentially enhance neuroprotective effects and improve CNS drug bioavailability in conditions such as Parkinson's disease. The companies are preparing IND-enabling studies and preclinical partnering discussions for Q4 2025, with NLS having recently raised approximately $7 million in equity financing and secured a $25 million equity line of credit to support operations following its planned merger with Kadimastem to form NewCelX.